Aclaris Therapeutics announces issuance of patent for the use of ruxolitinib
Aclaris Therapeutics announced that the United States Patent and Trademark Office, or USPTO, issued U.S. Patent No. 10,265,258 covering methods of treating alopecia areata, or AA, using ruxolitinib or isotopic forms of ruxolitinib. This newly issued patent is the latest in a series of patents granted by the USPTO which are exclusively licensed to Aclaris by The Trustees of Columbia University in the City of New York in connection with Aclaris' janus kinase, or JAK, inhibitor program for hair loss disorders. This IP arose out of the research conducted by Angela Christiano and her team at Columbia University. The claims in this issued patent cover the use of an effective amount of isotopic forms of ruxolitinib, including deuterated ruxolitinib, to treat AA.